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Objectives This study sought to evaluate the effect of age on procedure type, periprocedural management,
and in-hospital outcomes of patients undergoing lower-extremity (LE) peripheral vascular intervention (PVI).
Background Surgical therapy of peripheral arterial disease is associated with signiﬁcant morbidity
and mortality in the elderly. There are limited data related to the inﬂuence of advanced age on the
outcome of patients undergoing percutaneous LE PVI.
Methods Clinical presentation, comorbidities, and in-hospital outcomes of patients undergoing LE
PVI in a multicenter, multidisciplinary registry were compared between 3 age groups: 70 years,
between 70 and 80 years, and 80 years (elderly group).
esults In our cohort, 7,769 patients underwent LE PVI. The elderly patients were more likely to be fe-
male and to have a greater burden of comorbidities. Procedural success was lower in the elderly group
(74.2% for age 80 years vs. 78% for age 70 to 80 years and 81.4% in patients age 70 years, respec-
ively; p  0.0001). Unadjusted rates of procedure-related vascular access complications, post-procedure
ransfusion, contrast-induced nephropathy, amputation, and major adverse cardiac events were higher in
lderly patients. After adjustment for baseline covariates, the elderly patients were more likely to experi-
nce vascular access complications; however, advanced age was not found to be associated with major
dverse cardiac events, transfusion, contrast-induced nephropathy, or amputation.
onclusions Contemporary PVI can be performed in elderly patients with high procedural and
echnical success with low rates of periprocedural complications including mortality. These ﬁndings
ay support the notion of using PVI as a preferred revascularization strategy in the treatment of
evere peripheral arterial disease in the elderly population. (J Am Coll Cardiol Intv 2011;4:694–701)
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695Peripheral artery disease (PAD) represents a significant
problem in the United States, especially among the elderly
population (1–3). According to NHANES (National
Health and Nutrition Examination Survey) (1999 to 2000),
the prevalence of PAD among individuals 70 years was
14.5%, or nearly 4 million adults, with equal distribution
between sexes (2). As the prevalence and severity of PAD is
increased with age, so too are the risks associated with
surgical revascularization.
See page 702
Compared with younger patients, elderly patients who
undergo surgical interventions have higher 30-day and
1-year post-operative mortality; lack similar improvement in
functional outcomes, health perception, or well-being post-
operatively; have delayed return to normal activities; and
require increased use of hospital resources (1,4–8).
Peripheral vascular intervention (PVI) offers several the-
oretical advantages over surgical revascularization for the
treatment of PAD. PVIs are associated with lower overall
morbidity, can be performed with less anesthesia, have
minimal access site trauma, faster recovery times, shorter
hospitalizations, lower infection rates, less cardiovascular
stress, and present a viable option for patients deemed too
high risk for primary surgical management of lower limb
PAD (9–15). Although there has been significant growth in
PVI rates in the last several years, there is a paucity of
literature on the precise relationship between advanced age
and PVI outcomes. We examined this relationship between
advanced age, defined as age 80 years, and outcomes of
patients undergoing PVI in a multicenter PVI registry.
Methods
BMC2 PVI registry. The details of the BMC2 PVI (Blue
Cross Blue Shield of Michigan Cardiovascular Consortium
Peripheral Vascular Intervention) program have been de-
scribed previously (16). Supported by Blue Cross Blue
Shield of Michigan, BMC2 PVI is a prospective, multi-
center observational registry designed to collect information
on patients undergoing PVI in an effort to evaluate
evidence-based disease management and to support collab-
orative improvement in quality of care and outcomes. The
database was initiated in 2001, with multiple individual sites
contributing data since 2002. The registry currently collects
detailed information on consecutive patients who have
undergone PVI for clinical syndromes including claudica-
tion, critical limb ischemia, or uncontrolled hypertension.
Endovascular carotid interventions and abdominal aortic
stent grafts are not included in the registry because clinical
parameters for follow-up significantly differ in these pa-
tients. A data form is compiled for each patient, including
demographic information, past medical history, laboratoriespre- and post-PVI, patient history, presenting symptoms,
procedural indications, medication details, PVI type, details
of procedure, and associated complications if present. Data
quality and the inclusion of consecutive procedures are
ensured by ad hoc queries, random chart review, and a series
of diagnostic routines included in the database (16). A list of
standard definitions determined by the American College of
Cardiology Data Standards Committee has been used as a
reference. Periprocedural and in-hospital data are collected
from each individual. The registry has been approved by the
institutional review board of each participating hospital.
Data quality control. All data undergo a 3-step validation
process, including manual review for completeness and face
validity, review of rejected data forms during the import
process, and review of forms that fail diagnostic inquiries.
Additionally, a database manager checks all data forms for
completeness, and a random sample of data forms is
checked for face validity and clinical consistency. Twice
yearly, sites are audited by a nurse monitor from the co-
ordinating center where all cases
associated with severe complica-
tions and a randomly selected
5% of cases are audited for ac-
curacy. Variables on the origi-
nal data form are compared
with each patient’s hospital
chart, and all hard outcomes,
including any death, stroke,
amputation, or transfusion are
audited for accuracy. Incorrect
data are corrected and reen-
tered in the database.
Study patients and deﬁnitions. From
the 10,184 consecutive patients
who underwent PVIs between
January 2001 and December 2008, 8,052 cases were treated
exclusively for lower-extremity PAD. Of these, 283 cases
underwent a planned percutaneous intervention combined
with open vascular surgery during the same hospital admis-
sion and, hence, were discarded from this analysis. The
remaining 7,769 cases were divided into 3 age categories: 70
ears (n 4,017), between 70 and 80 years (n 2,350), and
80 years (n 1,402). All these cases were performed at 18
hospital centers that participate in the registry, and their
numbers ranged from 5 to 2,381 cases. Similar variations
were observed in adverse outcomes across the consortium.
All patients had confirmed PAD based on 1 or more of
the following: abnormal ankle brachial index, noninvasive
imaging studies (duplex ultrasound, computed tomographic
angiography, or magnetic resonance angiography), or an-
giography. Periprocedural, periodic follow-up data (death,
myocardial infarction [MI], transient ischemic attack [TIA],
stroke, limb ischemia requiring urgent surgery, renal failure,
Abbreviations
and Acronyms
CIN  contrast-induced
nephropathy
CVD  cerebrovascular
disease
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PAD  peripheral artery
disease
PVI  peripheral vascular
intervention
TIA  transient ischemic
attackdialysis, symptom status, ankle brachial index, Rutherford
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696score, walking distance, medications, risk factor status),
along with in-hospital clinical information were collected
prospectively by trained abstractors using a standardized
data collection form. Lower-extremity PVI patients were
categorized to 1 of 3 groups by symptom status of increasing
severity for the purpose of analysis: claudication, rest pain,
or limb salvage. Those in the rest pain and limb salvage
group are acknowledged to have critical limb ischemia.
Limb salvage was defined as patients who were undergoing
the PVI with the primary purpose of preventing or limiting
an amputation and in those with evidence of tissue loss
including ischemic ulcer or infection to aid in healing.
Contrast-induced nephropathy (CIN) was defined as
elevation in serum creatinine 0.5 mg/dl after PVI.
Major adverse cardiac events (MACE) were defined as
death, MI, or stroke/TIA. PVI procedural variables
included “technical success,” defined as vascular access,
deployment of device(s), and 30% diameter residual
stenosis after revascularization; and “procedural success,”
defined as technical success and freedom from major
periprocedural complications (17). Vascular access com-
plications were defined as a composite of retroperitoneal
hematoma, pseudoaneurysm, hematoma requiring trans-
fusion or associated with a decrease in hemoglobin 3
g/dl, arteriovenous fistula demonstrated by arteriography
or ultrasound, acute thrombosis, or need for surgical
repair of the access site.
Clinical characteristics, periprocedural, and in-hospital out-
comes were compared among patients across the 3 age groups.
Statistical analysis. Univariate association among the 3 lev-
ls of age variable with pre-procedural patient characteristics
ariables (2-level categorical) were determined by chi-square
r Fisher exact test. One-way analysis of variance was used
o compare the differences among continuous variables
ithin the 3 age categories. Transfusion rates, and individ-
al adverse events, including death, MI, cerebrovascular
isease/transient ischemic attack (CVD/TIA), CIN, and
ascular access complications were also compared among
he 3 age groups (18). Because significant associations
etween several adverse events and advanced age were
evealed by univariate analysis, separate multivariate logistic
egression models were developed for transfusion, MACE,
IN, vascular access complication, and amputation as de-
endent variables. Explanatory variables were chosen for
ach model by using stepwise forward selection method
p  0.05) to arrive at parsimonious models. The models
ere also forced to include 5 explanatory variables: sex; age
ategory 1 (70 years); age category 2 (70 to 80 years);
ge category 3 (80 years); and age-sex interaction variables.
ariables included in the multivariable models were: sociode-
ographic factors (sex, age, body mass index [lean, overweight,
nd obese]); historical clinical factors (MI, anemia, diabetes,
oronary artery disease, congestive heart failure, CVD/TIA,
nd creatinine clearance); procedural symptoms/indication glimb salvage, rest pain); pre-procedural medications (unfrac-
ionated heparin, low molecular weight heparin, angiotensin-
onverting enzyme inhibitor, beta-blocker, integrelin, abcix-
mab, statin, warfarin, and antiplatelet usage); procedural
ariables (procedure duration, heavily calcified vascular bed,
essel location [renal, iliac, femoropopliteal, below-the-knee];
nd device usage [stent, balloon, atherectomy, cryoballoon,
aser and cutting balloon]; and exceeding contrast dose (ex-
eeding a weight- and creatinine-adjusted maximum contrast
ose calculated using the formula: body weight in kilograms
cc/serum creatinine) (18,19). For creatinine clearance, 3.8%
f cases had either missing weight or pre-procedural creatinine
alues. These values were imputed to the median values based
n sex. Procedural duration values were missing in 1.3% of
ases and imputed to sex-based median values. Variables with
mputed values were used for multivariable logistic models
nly.
All tests used p  0.05 for the critical value of statistical
ignificance. All analyses were performed using SAS statistical
oftware (version 9.2, SAS Institute, Cary, North Carolina).
esults
Consecutive patients undergoing lower-extremity interven-
tions (aorto-iliac, femoropopliteal, and below-the-knee)
were prospectively enrolled from 18 hospital sites (Online
Appendix) in Michigan state during 2001 through 2008
(n  7,769). These patients were divided into 3 age groups:
70 years, between 70 and 80 years and those 80 years.
Baseline demographic and clinical characteristics among the
3 age groups are detailed in Table 1. Elderly patients were
more likely to be female and have a normal or lean body
mass index (25 kg/m2) or be anemic. In addition, patients
80 years were more likely to have a history of hyperten-
ion, congestive heart failure, or CVD/TIA than were other
ge groups. Patients in the 80-year age group were less
ikely to be current smokers than patients in other age
roups. Elderly patients presented with more severe PAD,
ncluding rest pain or the goal of limb salvage therapy
Fig. 1). In addition, the 80-years group had higher
emoropopliteal, below-knee, and multivessel (2 or more)
nterventions, whereas younger patients were more likely to
ndergo PVI for aortoiliac disease (Fig. 2). Technical
uccess as well as procedural success rates were higher in
oth the younger groups than in the elderly group (Fig. 3).
lderly patients were more likely to undergo balloon angio-
lasty or atherectomy, whereas younger patients were more
ikely to receive stents (48.7% in 70-years group vs. 42.8%
n 70-to-80-year group or 33.6% in 80-years group)
Table 2). Although retrograde access was more prevalent
83%) than antegrade access (17%) among all patients, our
tudy suggested that younger patients received more retro-
rade access than elderly patients did (84.5% in 70-year
roup vs. 81.8% in 70-to-80-year and 80.5% in the 80-
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 6 , 2 0 1 1 Plaisance et al.
J U N E 2 0 1 1 : 6 9 4 – 7 0 1 Peripheral Vascular Interventions in the Elderly
697year-old groups, p  0.004). By contrast, elderly patients,
who underwent more below-the-knee PVIs, were more
likely to undergo more antegrade access than the younger
groups were (p  0.01) (Table 2).
Table 1. Baseline Demographic and Clinical Characteristics by Age Group
<70 Yrs >70 to <80 Yrs >80 Yrs
Characteristics
(n  4,017)
(51.7%)
(n  2,350)
(30.3%)
(n  1,402)
(18.1%) p Value
Age, yrs 59.2 7.3 74.4 2.9 84.2 3.6 0.0001
Female 33.7 42.8 50.9 0.0001
Current smoker 45.3 19.1 7.8 0.0001
Lean, BMI 25
kg/m2
26.5 29.7 44.1 0.0001
Obese, BMI 30
kg/m2
41.2 32.6 19.1 0.0001
CAD 68.7 71.4 70.4 0.06
Diabetes 48.1 48.0 42.4 0.0006
HTN 87.3 92.8 94.6 0.0001
Hyperlipidemia 85.0 85.5 78.2 0.0001
CHF 16.8 21.8 25.7 0.0001
COPD 27.1 29.0 24.1 0.005
CVD/TIA 23.4 32.5 35.0 0.0001
Dialysis 4.6 4.2 2.7 0.01
Anemia 30.0 41.4 53.2 0.0001
Values are mean SD or % of N.
BMI bodymass index; CAD coronary artery disease; CHF congestive heart failure; COPD
chronic obstructive pulmonary disease; CVD cerebrovascular disease; HTN hypertension;
TIA transient ischemic attack.
Figure 1. Presenting Symptoms/Indications for Lower Extremity PVI Pro-
cedure Stratified by Age Group
The presenting symptoms or indications for peripheral vascular interven-
tion (PVI) procedure are stratiﬁed by age group. Rest pain and limb salvage
are not mutally exclusive.Periprocedural medication usage (pre-procedural and at
discharge) was lower in the elderly group (Table 3). Patients
80 years were less likely to be treated with statins or any
other lipid-lowering drugs. Whereas any antiplatelet usage
at discharge was high in all the groups, dual antiplatelet was
lower in the elderly group (63.4%) than in the younger
Figure 2. PVI Procedure Locations by Age Group
The arterial bed(s) treated during the peripheral vascular intervention (PVI)
procedure are stratiﬁed by age group.
Figure 3. PVI Technical or Procedural Success Differences Between
Age Groups
Peripheral vascular intervention (PVI) technical and procedural success
stratiﬁed by age group.
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698groups (71% and 69.4%, respectively in 70- and 70-to-
80-year groups).
Periprocedural complications were relatively low among
all age groups (Fig. 4). Those 80 years required more
blood transfusions and suffered more vascular access com-
plications. Despite a higher rate of MACE, CIN, and
amputation in the 80-year group, in-hospital death in all
Table 2. Procedural Access Type, Devices Used, and Vascular
Closure Method
Procedural Information <70 Yrs >70 to <80 Yrs >80 Yrs p Value
Access type*
Antegrade intervention 15.5 18.8 19.5 0.01
Retrograde intervention 84.5 81.8 80.5 0.004
Device usage
Balloon only 27.1 31.7 36.2 0.0001
Stent 48.7 42.8 33.6 0.0001
Atherectomy (with balloon) 14.1 16.0 18.1 0.001
Atherectomy (with stent) 3.6 3.7 4.3 0.4
Atherectomy only 12.7 14.9 16.0 0.0003
Cryoballoon 5.7 6.3 6.9 0.2
Cutting balloon 3.1 3.9 2.9 0.7
Laser 10.5 11.9 12.6 0.051
Closure device
Manual 61.9 61.8 60.2 0.5
Closure device 38.1 38.2 39.8 0.5
Values are % of N. *Access type (antegrade/retrograde) information was available only for 4,673
cases.
Table 3. Periprocedural Medication Usage
<70 Yrs >70 to <80 Yrs >80 Yrs p Value
Pre-procedural medication
usage
ACE inhibitor 50.8 45.6 43.2 0.0001
Beta-blocker 60.4 62.7 60.3 0.1
Statin 69.6 68.5 57.7 0.0001
Any lipid lowering 74.0 72.3 60.9 0.0001
Dual antiplatelet 48.2 45.7 39.7 0.0001
Any antiplatelet 86.2 86.2 82.8 0.004
Warfarin 5.3 7.5 7.1 0.001
Discharge medication
usage
ACE inhibitor 52.9 47.9 44.8 0.0001
Beta-blocker 64.3 66.1 65.8 0.3
Statin 74.2 74.7 63.7 0.0001
Any lipid lowering* 78.1 78.6 67.0 0.0001
Dual antiplatelet† 71.0 69.5 63.4 0.0001
Any antiplatelet‡ 94.2 94.4 93.7 0.6
Warfarin 9.8 13.9 15.1 0.0001
Values are%ofN. *Any lipid lowering is the choice of any lipid lowering agents.†Dual antiplatelet
is the choice of any 2 of the following: aspirin, clopidogrel, ticlopidine, or cilostazol. ‡Any
antiplatelet is the choice of any 1 or more of the following: aspirin, clopidogrel, ticlopidine, or
cilostazol.ACE angiotensin-converting enzyme.age groups were overall quite low and did not differ
significantly. There was no difference in the incidence of
MI, the need for repeat intervention, or TIA/stroke among
the 3 groups. Univariate analysis showed significantly higher
rates of MACE, transfusion, CIN, and amputation in the
elderly group; therefore, we used multivariate regression
modeling to determine whether advanced age was associated
with these outcomes. After multivariate adjustments (Fig. 5),
advanced age was found to be a predictor of vascular access
complication (odds ratio [OR]: 2.2, 95% confidence interval
[CI]: 1.2 to 3.9); by contrast, advanced age did not show any
independent correlation with post-PVI transfusion (OR: 1.08,
95% CI: 0.8 to 1.4, p  0.5), CIN (OR: 0.9, 95% CI: 0.6 to
1.4, p  0.9), or PVI-related MACE (OR: 1.3, 95% CI: 0.7
o 2.3, p  0.4), or amputation (OR: 0.7, 95% CI: 0.4 to 1.2,
 0.2). The C-statistic for models predicting vascular access
omplication, transfusion, CIN, amputation, and MACE were
.71, 0.82, 0.79, 0.91, and 0.82, respectively, suggesting ade-
uate model discrimination.
iscussion
In this multicenter, multidisciplinary, prospective registry
of patients undergoing PVI, elderly patients, as defined
by age 80 years, had more pre-existing comorbidities
including hypertension, congestive heart failure, and
CVD/TIA, as well as more frequent baseline anemia.
Figure 4. PVI Procedure Complication Differences by Age Group
PVI complications stratiﬁed by age group. **Contrast-induced nephropathy
(CIN) was deﬁned as an increase in serum creatinine 0.5 mg per deciliter
after PVI. MACE  major adverse cardiac event(s); MI  myocardial infarc-
tion; PVI  peripheral vascular intervention; TIA  transient ischemic
attack.Although current evidence suggests that the progression
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699of underlying PAD is similar whether patients have
symptoms, older patients in this study had more urgent
presentations, often presenting with less classic claudica-
tion symptoms and instead with more rest pain or with
the goal of limb salvage (1). Patients 80 years were also
more likely to undergo femoropopliteal, below-knee, or
multivessel arterial interventions (Table 2). Unadjusted rates
of periprocedural complications were relatively low among
all groups with a higher percentage of MACE, CIN,
transfusion, and vascular complications in the 80-year
group. However, after multivariate adjustments, these asso-
ciations were not significant.
PAD is highly prevalent, with a high incidence among
those with advanced age (1–3). As the U.S. population
continues to gray with the aging of the baby boomer
demographic, the treatment of PAD will continue to gain
greater significance, both because of its inherent morbidity
and because of the close association between PAD and
coexisting coronary and cerebrovascular disease (3). The
management of patients with severe PAD is often initially
focused on appropriate medical therapy and lifestyle
changes designed to improve symptoms, decrease the risk of
developing limb ischemia, and alter the risk profile for
cardiovascular morbidity and mortality. Surgical and endo-
vascular revascularization procedures are typically reserved
for patients with severe or lifestyle-limiting symptoms or
evidence of end organ ischemia related to their PAD (3).
Prognosis of the affected area is often determined by the
acuity of ischemia, the extent and location of PAD distri-
bution, and the rapidity of restoration of arterial circulation
to the area in question.
As the prevalence and severity of PAD are increased with
age, so too are the risks associated with surgical revascular-
Figure 5. Multivariate Predictions of Complications by Age Group (<70 Ye
Adjusted odds ratios with 95% conﬁdence intervals for complications displaye
ations as in Figure 4.ization. When compared with younger patients undergoingsurgical revascularization procedures for PAD, elderly pa-
tients have been shown to experience greater complication
burdens, have higher mortality, experience less satisfaction
post-operatively, have less improvement in functional out-
comes with delays in returning to normal activities, and
increased use of hospital resources (1,4–8,20–23). Accord-
ing to Conte et al. (23) in the 2006 multicenter, randomized
PREVENT III (Project or Ex-Vivo vein graft Engineering
via Transfection III) trial, mortality in elderly patients
undergoing lower-extremity bypass surgery ranged from 2%
to 10% with a surgical complication rate of 20% to 50%.
Also, in the 2007 prospective cohort study by Brosi et al.
(5), 376 consecutive patients presenting with 416 critically
ischemic legs from 1999 to 2004, the 30-day and 1-year
mortality rate was higher in octogenarians after surgical
revascularization when compared to younger (80 years)
patients in the same situation.
Compared to surgical revascularization, the growing pop-
ularity of PVI is because of the perception of lower overall
morbidity and mortality. In the 2007 prospective study by
DeRubertis et al. (24), 1,000 consecutive PVI between 2001
and 2006 were performed for claudication or limb-
threatening ischemia. The primary endpoints of the study
included patency at 6-month intervals, recurrence of clau-
dication, failure of wound healing, or need for major
amputation. PVI for chronic lower-extremity PAD was
associated with minimal mortality and 2-year patency
rates of 80% when performed in patients with claudica-
tion (24). Similar results have been shown with PVI for
femoral-popliteal, critical limb ischemia, and infraingui-
nal disease (25–29). It is also thought that PVI may not
preclude or alter subsequent surgeries and may be re-
ference Group)
ge group with the age 70 years cohort used as a reference group. Abbrevi-ars Re
d by apeated if necessary (30).
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700The effect that advanced age has on PVI procedural
success, safety, and complication rates had not been effec-
tively evaluated in multicenter studies until now. One
strength of this study is that approximately 30% of patients
were70 and80 years of age and 18% of cases were more
than 80 years. This number is the reflection of an aging
population. Interestingly, contrary to the higher risks asso-
ciated with surgical revascularization of PAD in elderly
patients, we found that for patients undergoing PVI, ad-
vanced age may not be a significant predictor of in-hospital
adverse events. Multivariate logistic models adjusted for age
and sex did not demonstrate a significant relationship
between age 70 years and MACE, transfusion, amputa-
ion, and CIN, respectively. However, advanced age showed
ignificant association with vascular access complication.
ortality was very low in all age groups, and no statistical
ifference was seen for MI, the need for repeat intervention,
r renal failure requiring dialysis as well.
According to uniform reporting standards in assessing
ndovascular treatments for chronic ischemia of lower limb
rteries (17), technical and procedural success are considered
important parameters for successful outcomes in PVI. In
his study, both technical and procedural success rates were
igh in the 70 and 70- to 80-year age groups (85% and
82.1%, respectively, for technical success; and 81.45% and
78%, respectively, for procedural success), whereas 80-
year-old group showed a lower technical as well as proce-
dural success rates (78.2% and 74.2%, respectively). We also
performed 2 subgroup analyses on patients with history of
diabetes and chronic renal failure to be able to understand
the contribution of age toward different outcomes (Online
Tables 1 and 2). Interestingly, the unadjusted pattern of
outcomes between the age groups in these 2 subgroups
remained the same as they were observed in the analyses that
included all patients. However, diabetes and chronic renal
failure remained 2 independent predictors of MACE, ampu-
tation, and CIN, respectively, by our multivariate analyses.
Study limitations. The results of this study are based upon
bservational data, and the outcomes were not centrally
djudicated. The use of a large registry, with clinical
eterogeneity and reporting variability, opens the possibility
or confounding variables and bias. However, our data are
ased on the largest registry of its type and reflect the
utcome of unselected patients undergoing PVI procedures
erformed by multiple specialists with different training
ackgrounds and provide a contemporary insight into treat-
ent in this population.
onclusions
Our data suggest that contemporary PVI can be performed
in elderly patients with high procedural and technical
success with a very low overall incidence of adverse events
and acceptably low mortality rates. These findings sup-port the use of PVI as the preferred method of revascu-
larization in the treatment of severe PAD in the elderly
population.
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